Share on StockTwits

Epizyme (NASDAQ:EPZM) Insider Eric Hedrick unloaded 2,000 shares of the stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $31.35, for a total value of $62,700.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Epizyme (NASDAQ:EPZM) traded down 3.57% during mid-day trading on Thursday, hitting $27.80. 212,924 shares of the company’s stock traded hands. Epizyme has a 1-year low of $18.10 and a 1-year high of $42.71. The stock has a 50-day moving average of $27.94 and a 200-day moving average of $27.13. The company’s market cap is $914.2 million.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.25. On average, analysts predict that Epizyme will post $-1.78 earnings per share for the current fiscal year.

A number of research firms have recently commented on EPZM. Analysts at Wainwright initiated coverage on shares of Epizyme in a research note on Tuesday. They set a “buy” rating and a $40.00 price target on the stock. Separately, analysts at HC Wainwright initiated coverage on shares of Epizyme in a research note on Tuesday. They set a “buy” rating and a $40.00 price target on the stock. Finally, analysts at Zacks upgraded shares of Epizyme from a “neutral” rating to an “outperform” rating in a research note on Wednesday, July 9th. They now have a $35.10 price target on the stock.

Epizyme, Inc is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.